A large-conductance (BK) potassium channel subtype affects both growth and mineralization of human osteoblasts.
The pharmacology of the large-conductance K(+) (BK) channel in human osteoblasts is not well defined, and its role in bone is speculative. Here we assess BK channel properties in MG63 cells and primary human osteoblasts and determine whether pharmacological modulation affects cell function. We used RT-PCR and patch-clamp methods to determine the expression of BK channel subunits and cell number assays in the absence and presence of BK channel modulators. RT-PCR showed the presence of KCNMA1, KCNMB1, KCNMB2, KCNMB3, and KCNMB4 subunits. The BK channel was voltage dependent, with a mean unitary conductance of 228.8 pS (n = 10) in cell-attached patches (140 mM K(+)/140 mM K(+)) and a conductance of 142.5 pS (n = 16) in excised outside-out and 155 pS (n = 6) in inside-out patches in 3 mM K(+)/140 mM K(+). The selectivity ratio (ratio of K(+) to Na(+) permeability) was 15:1. The channel was blocked by tetraethylammonium (TEA, 0.3 mM), iberiotoxin (5-60 nM), tetrandrine (5-30 microM), and paxilline (10 microM) and activated by isopimaric acid (20 microM). BK channel modulators affected MG63 cell numbers: TEA and tetrandrine significantly increased cell numbers at low concentrations (3 mM and 3 microM, respectively) and reduced cell numbers at higher concentrations (>10 mM and >10 microM, respectively). Neither iberiotoxin (20-300 nM) nor slotoxin (300 nM) affected cell numbers. The increase in cell numbers by TEA was blocked by isopimaric acid. TEA (0.1-3.0 mM) significantly increased mineralization in primary osteoblasts. In conclusion, the BK channel has a distinctive pharmacology and is thus a target for therapeutic strategies aimed at modulating osteoblast proliferation and function.
Henney
Neil C
NC
Welsh School of Pharmacy, Cardiff Univ., UK.
Li
Bo
B
Elford
Carole
C
Reviriego
Pablo
P
Campbell
Anthony K
AK
Wann
Kenneth T
KT
Evans
Bronwen A J
BA
D044182:Benzylisoquinolines / Q000494:pharmacology; D002113:Calcification, Physiologic / Q000187:drug effects / Q000502:physiology*; D002264:Carboxylic Acids / Q000494:pharmacology; D002452:Cell Count; D002455:Cell Division / Q000502:physiology*; D002460:Cell Line; D004396:Coloring Agents; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D051036:Large-Conductance Calcium-Activated Potassium Channels / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D010006:Osteoblasts / Q000166:cytology* / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D010455:Peptides / Q000494:pharmacology; D010539:Permeability / Q000187:drug effects; D010616:Phenanthrenes / Q000494:pharmacology; D026902:Potassium Channel Blockers / Q000494:pharmacology; D020033:Protein Isoforms / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019789:Tetraethylammonium / Q000494:pharmacology; D014343:Trypan Blue
D044182:Benzylisoquinolines; D002264:Carboxylic Acids; D004396:Coloring Agents; D007211:Indoles; D051036:Large-Conductance Calcium-Activated Potassium Channels; D010455:Peptides; D010616:Phenanthrenes; D026902:Potassium Channel Blockers; D020033:Protein Isoforms; C115138:isopimaric acid; C009438:tetrandrine; C048220:paxilline; D019789:Tetraethylammonium; C064719:iberiotoxin; D014343:Trypan Blue